1. Pink Sheet

Makary US FDA Nomination Advances, Last Minute Hiccup May Offer Clues On Mifepristone

 
• By Sarah Karlin-Smith

President Trump’s CDC director nominee was pulled after vaccine positions appeared too extreme for some Republicans, but the nominations to lead the FDA and NIH advanced to the Senate floor despite last-minute drama.

Sen. Josh Hawley, R-MO, speaks about the resignation of Hilary Perkins as FDA chief counsel. (Screenshot of Senate Broadcast)

Despite late drama that may signal a coming change in mifepristone policy, Martin Makary appears likely to become the next US Food and Drug Administration Commissioner following a positive bipartisan vote from the Senate Health, Education, Labor and Pensions Committee.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

More from Vaccines